On the primary endpoints of the study, combined cardiovascular mortality and worsening heart failure events (α = 0.04) were ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

Payers and employers have tightened access to the glucagon-like peptide 1 receptor agonist class once these therapies became ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...